PT1981909T - Péptidos antigénicos do gm-csf e anticorpos contra o gm-csf - Google Patents

Péptidos antigénicos do gm-csf e anticorpos contra o gm-csf

Info

Publication number
PT1981909T
PT1981909T PT77635142T PT07763514T PT1981909T PT 1981909 T PT1981909 T PT 1981909T PT 77635142 T PT77635142 T PT 77635142T PT 07763514 T PT07763514 T PT 07763514T PT 1981909 T PT1981909 T PT 1981909T
Authority
PT
Portugal
Prior art keywords
csf
antigenic
antibodies
peptides
csf peptides
Prior art date
Application number
PT77635142T
Other languages
English (en)
Inventor
Grasso Luigi
M Sass Philip
C Nicolaides Nicholas
Li Jian
Chao Qimin
Routhier Eric
Ebel Wolfgang
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38345964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1981909(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of PT1981909T publication Critical patent/PT1981909T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PT77635142T 2006-02-08 2007-02-08 Péptidos antigénicos do gm-csf e anticorpos contra o gm-csf PT1981909T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77125106P 2006-02-08 2006-02-08
US77450006P 2006-02-17 2006-02-17

Publications (1)

Publication Number Publication Date
PT1981909T true PT1981909T (pt) 2017-01-18

Family

ID=38345964

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77635142T PT1981909T (pt) 2006-02-08 2007-02-08 Péptidos antigénicos do gm-csf e anticorpos contra o gm-csf

Country Status (18)

Country Link
US (5) US7741450B2 (pt)
EP (2) EP3181585A3 (pt)
JP (1) JP5210889B2 (pt)
KR (2) KR101486183B1 (pt)
CN (1) CN101501070B (pt)
AU (1) AU2007213716C1 (pt)
CA (2) CA2961031C (pt)
CY (1) CY1118709T1 (pt)
DK (1) DK1981909T3 (pt)
ES (1) ES2609088T3 (pt)
HR (1) HRP20170024T1 (pt)
HU (1) HUE032584T2 (pt)
IL (2) IL193011A (pt)
LT (1) LT1981909T (pt)
PL (1) PL1981909T3 (pt)
PT (1) PT1981909T (pt)
RS (1) RS55526B1 (pt)
WO (1) WO2007092939A2 (pt)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE025134T2 (en) 2005-04-18 2016-01-28 Amgen Res (Munich) Gmbh Human Granulocyte Macrophage Colony Stimulation Factor Antibodies
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
WO2007092939A2 (en) 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf
EP2013620A2 (en) * 2006-04-17 2009-01-14 Morphotek, Inc. Whole genome evolution technology applied to improve protein and antibody yields by cells
US8398972B2 (en) * 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
NZ598345A (en) * 2006-11-21 2013-09-27 Kalobios Pharmaceuticals Inc Methods of treating chronic inflammatory diseases using a gm-csf antagonist
US20100255513A1 (en) * 2007-03-30 2010-10-07 Denson Lee A Serological markers of inflammatory bowel disease phenotype and disease progression
EP2190469B1 (en) 2007-09-04 2015-02-25 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
AU2008323608A1 (en) * 2007-11-12 2009-05-22 Crc For Asthma And Airways Ltd Epitope for neutralizing antibodies
DK2215119T3 (da) 2007-11-13 2013-02-04 Evec Inc Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme.
JP2012105657A (ja) * 2008-02-14 2012-06-07 Evec Inc ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物
JP5476310B2 (ja) * 2008-02-14 2014-04-23 株式会社イーベック ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物
JP5608635B2 (ja) 2008-04-07 2014-10-15 カロバイオス ファーマシューティカルズ インコーポレイティッド 心不全処置のためのｇｍ−ｃｓｆの中和方法
EA201001691A1 (ru) * 2008-04-28 2011-10-31 Калобайос Фармасьютикалз, Инк. Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
JP5771140B2 (ja) * 2008-04-29 2015-08-26 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 治療用のｇｍ−ｃｓｆおよびｉｌ−１７阻害剤
SI2376121T1 (sl) * 2008-12-22 2016-07-29 The University Of Melbourne Zdravljenje osteoartritisa
ES2685895T3 (es) 2008-12-22 2018-10-15 The University Of Melbourne Tratamiento del dolor
CN102459340A (zh) * 2009-04-23 2012-05-16 特罗科隆科学有限公司 粒性白血细胞-巨噬细胞菌落-刺激因子(gm-csf)中和抗体
US8828668B2 (en) 2010-02-11 2014-09-09 The Board Of Trustees Of The Leland Stanford Junior University Markers for determination of patient responsiveness
US9428574B2 (en) 2011-06-30 2016-08-30 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
JP2014520784A (ja) * 2011-07-06 2014-08-25 モルフォシス・アー・ゲー 抗ｃｄ２０抗体と抗ｇｍ−ｃｓｆ抗体との治療的組合せおよびその使用
US9901079B2 (en) 2011-08-18 2018-02-27 New York University Inhibition of oncogenic kras-induced GM-CSF production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
CN104185681A (zh) 2012-02-01 2014-12-03 卡姆普根有限公司 C1orf32抗体及其用于治疗癌症的用途
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
CN104212760B (zh) * 2013-05-29 2017-08-08 中国科学院上海生命科学研究院 肌肉干细胞体外培养方法及其应用
CA2922251C (en) 2013-08-30 2023-10-17 Takeda Gmbh Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
CA2946230A1 (en) 2014-05-07 2015-11-12 Takeda Gmbh Liquid formulation comprising gm-csf neutralizing compound
ES2626491B1 (es) 2015-12-03 2018-06-25 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpos monoclonales frente a bambi y uso para tratamiento de enfermedades inflamatorias
CN107840886B (zh) * 2016-09-19 2020-11-10 天境生物科技(上海)有限公司 Gm-csf抗体及其用途
CA3036509C (en) 2016-09-19 2022-10-25 I-Mab Anti-gm-csf antibodies and uses thereof
CN109963570A (zh) 2017-01-21 2019-07-02 宁波知明生物科技有限公司 芍药苷-6’-o-苯磺酸酯在治疗干燥综合征的应用
EP3634487A4 (en) * 2017-06-09 2021-03-24 The Regents Of The University Of Colorado, A Body Corporate, A Colorado Non-Profit GM-CSF MIMETICS AND PROCESSES FOR THE PRODUCTION AND USE OF THEM
US10899831B2 (en) 2017-10-02 2021-01-26 Humanigen, Inc. Method of reducing the level of non-GM-CSF cytokines/chemokines in immunotherapy-related toxicity
US11130805B2 (en) 2017-10-02 2021-09-28 Humanigen, Inc. Methods of treating CART-T cell therapy-induced neuroinflammation using a GM-CSF antagonist
US10927168B2 (en) 2017-10-02 2021-02-23 Humanicen, Inc. Method of reducing tumor relapse rate in immunotherapy by administration of lenzilumab
US11673962B2 (en) 2017-10-02 2023-06-13 Humanigen, Inc. Method of increasing the efficacy of CAR-T immunotherapy using lenzilumab
US11655293B2 (en) * 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
EP3827016A4 (en) * 2018-10-15 2022-05-04 Elixiron Immunotherapeutics (Hong Kong) Limited ANTIBODIES TO GRANULOCYTE AND MACROPHAGE GROWTH FACTOR AND THEIR USES
JP2022513412A (ja) * 2018-10-31 2022-02-07 ヒューマニゲン インコーポレイティッド 癌を治療するための物質及び方法
WO2021207667A1 (en) * 2020-04-10 2021-10-14 Kinevant Sciences Gmbh Compositions and methods for treating lung injury or acute respiratory distress syndrome (ards)
CN117384856B (zh) * 2023-09-04 2024-04-16 广州医科大学 一种永生化copd人支气管上皮细胞株及其构建方法和应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU594014B2 (en) 1984-03-21 1990-03-01 Research Corporation Technologies, Inc. Recombinant DNA molecules
US5908763A (en) 1984-07-06 1999-06-01 Novartis Corporation DNA encoding GM-CSF and a method of producing GM-CSF protein
NZ218336A (en) * 1985-12-09 1991-08-27 Kirin Amgen Inc Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
US5260273A (en) 1988-01-06 1993-11-09 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US5164369A (en) 1988-01-06 1992-11-17 The Scripps Research Institute Pulmonary surfactant protein and related polypeptide
US6013619A (en) 1988-01-06 2000-01-11 The Scripps Research Institute Pulmonary surfactants and therapeutic uses, including pulmonary lavage
US6613734B2 (en) 1988-01-06 2003-09-02 The Scripps Research Institute Peptides-containing liposomal surfactants
EP0482086A1 (en) 1989-07-14 1992-04-29 Schering Corporation Antagonists of gm-csf derived from the carboxyl terminus
CA2060741A1 (en) * 1991-02-11 1992-08-12 Robert S. Greenfield Gm-csf inhibiting oligopeptides
BR9205151A (pt) 1992-08-17 1994-03-01 Praxair Technology Inc Dissolucao aumentada de gas
WO1997035559A2 (en) 1996-03-27 1997-10-02 Ortho Pharmaceutical Corporation Manufacture of liposomes and lipid-protein complexes by ethanolic injection and thin film evaporation
WO1997035882A1 (en) 1996-03-27 1997-10-02 Ortho Pharmaceutical Corporation Lyophilized pulmonary surfactant peptide compositions
US6013764A (en) 1996-07-17 2000-01-11 Ortho Pharmaceutical Corp. Liquid phase peptide synthesis of KL-4 pulmonary surfactant
EP0959136A1 (en) * 1998-05-20 1999-11-24 Introgene B.V. Targeted delivery through a cationic amino acid transporter
US7108852B2 (en) 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
DE60214682T2 (de) 2001-03-08 2007-09-13 Merck Patent Gmbh Modifizierter humaner granulozyten makrophagen kolonien stimulierender faktor (gm-csf) mit reduzierter immunogenität
JP2006500905A (ja) 2002-02-13 2006-01-12 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ ヒト化ｇｍ−ｃｓｆ抗体
US7754450B2 (en) 2002-11-15 2010-07-13 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
US7396915B2 (en) * 2003-02-28 2008-07-08 Mitsubishi Pharma Corporation Monoclonal antibody and gene encoding the same, hybridoma, pharmaceutical composition, and diagnostic reagent
JP2005040126A (ja) * 2003-02-28 2005-02-17 Mitsubishi Pharma Corp モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬
AU2004263514A1 (en) 2003-08-05 2005-02-17 Morphotek, Inc. A variant cell surface molecule associated with cancer
JP2005176792A (ja) 2003-12-24 2005-07-07 Atex Co Ltd 乗用草刈機
EP1593690B1 (en) * 2004-05-05 2009-07-01 Micromet AG Preparation of ScFv antibody fragments
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
HUE025134T2 (en) * 2005-04-18 2016-01-28 Amgen Res (Munich) Gmbh Human Granulocyte Macrophage Colony Stimulation Factor Antibodies
PT3620171T (pt) * 2005-05-18 2022-06-30 Morphosys Ag Anticorpos anti-gm-csf e suas utilizações
JP4736037B2 (ja) 2005-10-26 2011-07-27 株式会社イーベック ヒトｇｍ−ｃｓｆに結合するヒトのモノクローナル抗体並びにその抗原結合部分
WO2007092939A2 (en) 2006-02-08 2007-08-16 Morphotek, Inc. Antigenic gm-csf peptides and antibodies to gm-csf

Also Published As

Publication number Publication date
WO2007092939A3 (en) 2008-03-27
KR101486183B1 (ko) 2015-01-28
US20100272730A1 (en) 2010-10-28
CA2641169C (en) 2017-05-02
CA2641169A1 (en) 2007-08-16
AU2007213716A1 (en) 2007-08-16
IL193011A0 (en) 2009-02-11
HUE032584T2 (en) 2017-09-28
US20080292641A1 (en) 2008-11-27
ES2609088T3 (es) 2017-04-18
WO2007092939A2 (en) 2007-08-16
CA2961031C (en) 2020-02-25
CA2961031A1 (en) 2007-08-16
US20140086928A1 (en) 2014-03-27
KR20130124420A (ko) 2013-11-13
HRP20170024T1 (hr) 2017-03-10
WO2007092939A8 (en) 2009-07-23
CY1118709T1 (el) 2017-07-12
US9422367B2 (en) 2016-08-23
EP1981909B1 (en) 2016-10-12
IL235050A (en) 2017-03-30
EP3181585A3 (en) 2017-08-30
US20130058945A1 (en) 2013-03-07
US20160333089A1 (en) 2016-11-17
CN101501070A (zh) 2009-08-05
KR20080099314A (ko) 2008-11-12
US10023632B2 (en) 2018-07-17
US8623364B2 (en) 2014-01-07
EP3181585A2 (en) 2017-06-21
CN101501070B (zh) 2013-12-25
JP5210889B2 (ja) 2013-06-12
US8318168B2 (en) 2012-11-27
AU2007213716C1 (en) 2015-05-07
RS55526B1 (sr) 2017-05-31
KR101395515B1 (ko) 2014-05-14
DK1981909T3 (en) 2017-01-23
LT1981909T (lt) 2017-01-10
PL1981909T3 (pl) 2017-08-31
AU2007213716B2 (en) 2012-12-06
EP1981909A2 (en) 2008-10-22
US7741450B2 (en) 2010-06-22
JP2009526082A (ja) 2009-07-16
IL193011A (en) 2015-06-30

Similar Documents

Publication Publication Date Title
HRP20170024T1 (hr) Antigeni peptidi gm-csf i protutijela protiv gm-csf
ZA200900395B (en) Antibodies directed to +-Vß6 and uses thereof
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
IL195658A0 (en) Anti-nkg2a antibodies and uses thereof
ZA201002160B (en) Human gm-csf antigen binding proteins
IL192419A0 (en) Anti-ephb4 antibodies and methods using same
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
GB0601102D0 (en) Kinase Peptides And Antibodies
IL214433A (en) Anti-3 fgfr antibodies and methods of use
IL216731A (en) And antibodies against p95 – her2 and their uses
HK1142341A1 (en) Anti-hepcidin antibodies and uses thereof
EP2089053A4 (en) VACCINE COMPOSITIONS BASED ON HPV ANTIGEN FUSION PROTEIN AND USES THEREOF
ZA201001260B (en) Immunogenic polypeptides and monoclonal antibodies
IL203221A (en) Bioactive peptides and antibodies
IL212040A0 (en) Hepatitis c antibodies and uses thereof
IL236237A (en) Tmem154 antibodies and their segments and uses
IL231891A0 (en) Anti-2ephriinb antibodies and methods of using them
EP2388320A4 (en) ANTI-HS6ST2 ANTIBODIES AND USE THEREOF
EP2322610A4 (en) ANTI-CLCP1 HUMAN ANTIBODIES AND USE THEREOF
HK1158977A1 (zh) 抗膜鐵轉運蛋白 單克隆抗體及其用途
ZA200806053B (en) Anti-EphB4 antibodies and methods using same
GB0617564D0 (en) Peptides and methods
EP2540742A4 (en) MONOCLONAL ANTIBODIES OF ANTI-CYR61 PROTEIN AND USES THEREOF
GB0823492D0 (en) Antigenic peptides and uses thereof
PL380695A1 (pl) Sposób otrzymywania peptydów o charakterze epitopów wiążących immunoglobuliny IgE